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Thymidylate synthase (TS) catalyzes methylation of dUMP to dTMP and it is the target for the 5-Fluorouracil (5-FU) activity.
Barbour et al. showed that variant structural forms of TS in tumour cell lines confer resistance to ﬂuoropyrimidines. We planned
to perform the whole TS gene structure by means of sequencing techniques in human colorectal cancer (CRC) samples to try to
identify the presence of any possible TS variant form that could be responsible of ﬂuoropyrimidines drug resistance and of the
worse prognosis. We performed the TS-DNA gene sequence in 68 CRC from patients of A, B, and C Dukes’ stages and diﬀerent
histological grade, but we did not ﬁnd any mutation in the TS-DNA structure. In the future we intend to widen the TS structure
analysis to the metastatic CRCs, because due to their higher genomic instability, they could present a TS variant form responsible
of the ﬂuoropyrimidines drug resistance and the worse prognosis.
1.Introduction
TS is a key enzyme in the de novo synthesis of dTMP, an
essential precursor of DNA, which catalyses the methylation
of dUMP to dTMP [1].
The critical role of TS in the nucleotide metabolism has
made it an important target of a variety of chemotherapeutic
agents including 5-FU, 5-FU prodrugs as capecitabine, and
novel folate-based TS inhibitor such as raltitrexed and
pemetrexed, used in the treatment of colorectal and other
solid tumours [2]. Resistance to ﬂuoropyrimidines and other
TS inhibitors may occur through a variety of mechanisms
including elevated intracellular TS levels resulting from
increases in TS transcription [3] and translation [4].
In CRC patients the TS intratumoural expression may
predict for the sensitivity to 5-FU and other TS inhibitor-
based chemotherapies [5, 6] and may also be an important
prognostic marker [7]. High TS expression in early stage
CRC patients seems to predict for poorer overall survival in
both chemotherapy-treated and untreated patients following
surgery [4]. Also, metastatic CRC patients with high TS
levels are unlikely to respond to infusional treatment with
5-FU, whereas patients with low TS levels have higher than
average response rate [8, 9] .I nap r e v i o u ss t u d y ,h o w e v e r ,w e
demonstrated that higher TS levels are favourable prognostic
factors for disease free and overall survival [10]. To date the
real value of the TS level as prognostic factor is doubtful and
some authors are in disagreement about it [11] .T h eT Sg e n e ,
containing 7 coding exons, is located in chromosome 18q,
for which a high percentage of monosomic loss has been
reported to be cell-cycle dependent, although some recent
evidence points are more oriented towards proliferation-
dependence. It can be predicted that mutations in the TS
gene might result in a modiﬁcation of its structure and
then in its ability to interact with the ﬂuoropyrimidines.
This prediction has been born out in a variety of studies2 Journal of Nucleic Acids
Table 1: Clinical features of patients
No. of patients 68
Median age 67
Sex
Male 30
Female 38
Table 2: Site of primary tumour.
Right colon 21
Left colon 34
Rectum 13
[12–15]. S. H. Berger and F. G. Berger reported that
the human colon tumour cell line HCT116 produces a
variant structural form of TS, in addition to the common
form found in all colon cell lines tested. Among the TS
overproduction derivatives of HCT116, cells overexposing
the novel forms are more resistant to FdUrd, compared
with cells overexpressing the normal form [15]. So, an
association between drug response and altered TS structure
could suggest that the novel TS form, which is encoded
by a variant structural TS gene, confers relative resistance
to FdUrd [1]; this was supported by preliminary kinetic
data indicating that this novel form has a reduced aﬃnity
for FdUMP [16]. This variant form presents a replacement
of an evolutionary conserved tyrosine by a histidine at
residue 33 of the TS polypeptide [17, 18]; this mutation
represents the only diﬀerence between the two TS forms and
must account for the structural and functional diﬀerences
between them. In an our previous paper we performed the
analysis of the TS structure in patients bearing CRC to try
to demonstrate the presence of that speciﬁc mutation, but
we did not ﬁnd it in any patient [19]. Here, we intend to
proceed on the use of sequencing techniques to see if any
TS variant form could be present in human cancer samples
from patients who underwent surgery for primary colorectal
cancer and previously untreated and try to ﬁnd relationship
between any hypothetical TS variant form with the 5-FU
treatment.
We performed the TS-DNA gene sequence in 68 cancer
samples from patients of diﬀerent Dukes’ stages (A, B, and
C) and histological grade but we did not ﬁnd any change in
the TS-DNA structure.
2.MaterialsandMethods
2.1. Patients. TS structure was assessed in a series of 68
patients who underwent surgery for primary colorectal car-
cinoma conﬁrmed histologically and previously untreated.
The following exclusion criteria were applied: history of
other neoplasias apart of CRC and death occurring within
30 days following surgery and due to postoperative com-
plications. The tumours were staged and graded according
Dukes’ system and their clinicopathological features were
summarised in Tables 1, 2,a n d3.
Table 3: Tumour staging and grading.
Tumour staging
Dukes A 10
Dukes B 27
Dukes C 31
Grading
G1 7
G2 36
G3 25
Table 4: Primer sequences.
Prim name Primer sequence
1 F CGCCGCGCCACTTCGC
1 R CTCCCCAGCCGCGCCTCC
2 F GGATGGCATGATCTGTC
2 R CTGCTGTGTTGAGAACAG
3 F CAACTGAGATGGCTTAAG
3 R GCAAACACGTGCTAGGAAGG
4 F GCCATCTCATGACATG
4 R CCCTCAGTGCCTCTGCAC
5 F CTTTGCCTTTAGCTGTG
5 R GAGCTCATGTGGTAGGCT
6 F GCGGTGTCTGCATATT
6 R GCATTGAGCAGATACCTG
7 F CACGGACATGAGGAGC
7 R CTAAAGACTGACAATATC
2.2. Colorectal Tumour Samples. Primary tumour and cor-
responding colonic mucosa were obtained with informed
consent from patients. The samples at surgery were divided
in two parts: one was frozen at −80
◦ until analysis, and
the other portion was embedded in paraﬃnt oc o n ﬁ r m
histologically the absence of contamination by normal and
necrotic tissue and lymphocytes.
2.3. Extraction of Genomic DNA, PCR Analyses, and Sequenc-
ing. Genomic DNA was extracted from tumour and mucosa
samples with a commercial Kit purchased from Qiagen
(Kjvenlo, The Netherlands) and stored at −20
◦.
The TS gene of tumour and mucosa samples was ampli-
ﬁed in seven diﬀerent PCR reactions using DNA primers of
16–20 bases in length placed in the adjacent intronic regions
o fe x o n s1 ,2 ,3 ,4 ,5 ,6 ,a n d7a n dl i s t e di nTable 4.
Ampliﬁcation was performed using a Perkin Elmer
model 2400 thermal cycler (Boston USA). Reaction mixture
included 5µL of 10% dimethylsulfoxide, 5µLo f1 0× buﬀer,
1.5µLo f1 . 5 m MM g C l 2,1 µL of 10mM dNTPs, 200–
500ng of genomic DNA, 200pmol of both upstream and
downstream primers, and 1 Units of Taq DNA polymerase,
in a ﬁnal volume of 50µL. Ampliﬁcation was run for 35
cycles with each cycle consisting in a denaturation step at
95◦C for 1 minutes, a primer annealing step at 51◦Cf o r
1 minute, and an extention step at 72◦Cf o r2m i n u t e s .
PCR was terminated by incubation at 72◦Cf o r1 0m i n u t e s .Journal of Nucleic Acids 3
The length of the ampliﬁcation products ranged from 180 to
310 bases. Ampliﬁed fragments were analysed by agarose gel
and visualized by ethidium bromide staining. DNA samples,
generated with independently repeated PCR products, were
sequenced with the SequiTherm EXCEL II DNA sequencing
kit (Epicenter, Madison, WI) on a LI-COR 4000 (MWG-
Biotech, Ebersberg, Germany) sequencer.
3. Results
The enzyme structure obtained by sequencing the TS
genomic DNA of each sample was performed in 68 patients
with operable CRC, untreated with previous chemotherapy.
Primary tumours and corresponding colonic mucosa were
obtained from each patient and the TS genomic structure
was performed on each of them, after histological control.
7 patients had G1 histological grade, 36 had G2, and 25 had
G3 histological grade; 10 patients had Dukes’ A tumours, 27
patients had Dukes’ B, and 31 patients had Dukes C cancers.
The median age of patients was 67 years; 30 patients were
male and 38 female. In all the tumour samples evaluated
we did not ﬁnd any TS-DNA variant structure in tumour:
all A, B, and C Dukes’ patients showed stable TS-DNA, and
also in the germline genome no TS-DNA variants have been
observed.
4. Discussion
The structure of the macromolecular target of a cytotoxic
drug is a critical determinant of cellular sensitivity to that
drug. Recently, TS has become the subject of several studies
aimed to elucidate a possible “clinical” role of TS detection
either as determinant of drug resistance or as prognostic
marker of the disease and predictive factor of the treatment.
Many studies are currently examining the real value of
TS expression levels as a prognostic factor, but in the mean
time signiﬁcant uncertainty prevails; whatever its prognostic
inﬂuence, to date no studies have been able to establish a
“cut-oﬀ” that is important for clinical usage. On the whole,
all of these in vitro studies have promising implications in
the study of the role of TS in clinical practice.
Moreover, the unclear meaning of “levels” not only as
a prognostic indicator but also as marker predictive of
resistance could be due to mechanisms diﬀerent from over
expression, as mutation.
In fact some authors focused their attention on the TS
structure with a double aim: development of a new classes
of TS-inhibitors with a diﬀerent mechanism of action and
generation of TS mutants to develop gene-therapy strate-
gies. Berger and coworkers showed that a single naturally
occurring change, a Tyr to His replacement, in the primary
structure of the TS molecule confers relative resistance to the
TS-directed antimetabolite FdUrd in HCT 116 cells. The Tyr
to His mutation is the only diﬀerence between the altered
form of TS and the normal form and, therefore, must be
responsible for the diminished eﬀectiveness of the enzyme
as a drug target.
The data in those studies, together with previously
published experiments, strongly favour the notion that the
Tyr to His’ mutation is responsible for the relative FdUrd
resistance of cell line HCT 116 [15, 16]. However, as
noted earlier, it is quite possible that factors in addition
to this mutation contribute to the phenotype of HCT116
and other colon cell lines. The frequency of the Tyr33
to His33 mutation in the normal and in the pathological
human populations is unknown. The altered TS may exist
as a polymorphism in humans [16]; alternatively, it may
have spontaneously arisen during tumorigenesis or during
establishment of the cell lines in culture.
Distinguishing among these possibilities will be of great
utility in assessing whether variant forms of TS identiﬁed in
cultured cell lines are segregating in the human population
and have an impact upon clinical response to 5-ﬂuorouracil
therapy in cancer patients. On the basis of this knowledge we
hoped to see if in human CRC samples it could be possible
to ﬁnd the same Tyr33 to His33 substitution in the TS
structure and eventually to correlate this ﬁnding with some
clinicopathological parameters such as age and sex, tumour
size and location, histological grade, Dukes’ stage, 5-FU and
Raltitrexed treatment, and disease free and overall survivals,
to see if that point mutation could be considered a reliable
marker of drug resistance and of prognosis. In those samples
we did not ﬁnd that point mutation at the codon 33 [19].
In this study we intend to proceed on the use of
sequencing techniques to see if any TS variant form could
be present in human cancer samples from patients who
underwent surgery for primary colorectal cancer (CRC) and
previously untreated and try to ﬁnd a relationship between
any hypothetical TS variant form with the 5-FU treatment
and prognosis.
We performed the TS-DNA gene sequence in 68 cancer
samplesfrompatientsofdiﬀerentDukes’stages(A,B,andC)
and histological grade, but we did not ﬁnd any mutation in
the TS-DNA structure. The conclusions that could be drown
are that in Dukes’ A, B, and C CRCs there are no changes in
the TS-DNA gene structure and that the evaluation of the TS
expression is the main CRC prognostic and drug response
marker. What remains is to evaluate the TS gene structure
of the D metastatic Dukes’ CRCs: in these tumours it
might be possible to ﬁnd TS-DNA structural changes related
with their higher genomic instability and this fact could
give an explanation of the 5-FU drug resistance and worse
prognosis.
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